These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16932362)

  • 1. Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection.
    Panchapakesan U; Chen XM; Pollock CA
    Nat Clin Pract Nephrol; 2005 Nov; 1(1):33-43. PubMed ID: 16932362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential.
    Yang J; Zhang D; Li J; Zhang X; Fan F; Guan Y
    Clin Sci (Lond); 2009 Jan; 116(1):17-26. PubMed ID: 19037881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V; Viswanathan P
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?
    Boulanger H; Mansouri R; Gautier JF; Glotz D
    Nephrol Dial Transplant; 2006 Oct; 21(10):2696-702. PubMed ID: 16880183
    [No Abstract]   [Full Text] [Related]  

  • 6. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
    Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
    Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
    Okada T; Wada J; Hida K; Eguchi J; Hashimoto I; Baba M; Yasuhara A; Shikata K; Makino H
    Diabetes; 2006 Jun; 55(6):1666-77. PubMed ID: 16731829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
    Chetty VT; Sharma AM
    Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular effects of PPARgamma activators - from bench to bedside.
    Marx N; Walcher D
    Prog Lipid Res; 2007 Nov; 46(6):283-96. PubMed ID: 17637478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
    Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
    Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptors and angiogenesis.
    Biscetti F; Straface G; Pitocco D; Zaccardi F; Ghirlanda G; Flex A
    Nutr Metab Cardiovasc Dis; 2009 Dec; 19(11):751-9. PubMed ID: 19628379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinediones and PPARγ agonists: time for a reassessment.
    Cariou B; Charbonnel B; Staels B
    Trends Endocrinol Metab; 2012 May; 23(5):205-15. PubMed ID: 22513163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of PPARs in the microvascular dysfunction in diabetes.
    Vinik A; Parson H; Ullal J
    Vascul Pharmacol; 2006 Jul; 45(1):54-64. PubMed ID: 16784897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging therapeutic strategies in diabetic nephropathy.
    Ravera M; Re M; Weiss U; Deferrari L; Deferrari G
    J Nephrol; 2007; 20 Suppl 12():S23-32. PubMed ID: 18050139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
    Cha DR; Zhang X; Zhang Y; Wu J; Su D; Han JY; Fang X; Yu B; Breyer MD; Guan Y
    Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
    Díaz-Delfín J; Morales M; Caelles C
    Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P; Rose M; Singh M
    Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of PPAR ligands in the management of diabetic nephropathy.
    Balakumar P; Arora MK; Singh M
    Pharmacol Res; 2009 Sep; 60(3):170-3. PubMed ID: 19646656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The complex role of PPARgamma in renal dysfunction in obesity: managing a Janus-faced receptor.
    Dobrian AD
    Vascul Pharmacol; 2006 Jul; 45(1):36-45. PubMed ID: 16716756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPARgamma and atherosclerosis.
    Staels B
    Curr Med Res Opin; 2005; 21 Suppl 1():S13-20. PubMed ID: 15811195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.